Comparison Between Haparin & Herodin in HD

Status Not yet recruiting

Clinical Trial Summary

The goal of this study is to compare the efficacy and drawbacks of Heparin and Hirudin in Haemodialysis patients. The main question it aims to answer is: which drug is more safe in Haemodialysis?

Clinical Trial Description

Extracorporeal thrombogenesis is a major problem associated with haemodialysis. The composition of the artificial membrane in the extracorporial system and large surface area to which the blood is exposed, contribute significantly to activation of the coagulation cascade and platelets. The use of anticoagulant is to prevent thrombotic occlusion of the dializer to ensure effective dialysis. The most common anticoagulant options for Hemodialysis include unfractionated heparin (UFH), low-molecular weight heparin (LMWH), thrombin antagonists, and platelet inhibiting agents. The choice of anticoagulant for Haemodialysis should be determined by patient characteristics, local expertise, and ease of monitoring. Heparins are currently the anticoagulants of choice in long-term haemodialysis (HD), but because of their shortcomings, including the increasing incidence of heparin-induced thrombocytopenia (HIT II), alternative anticoagulation is necessary, as there are several complication associated with its long term use, They include thrombocytopenia, increase bleeding tendency, osteoporosis, increase lipolytic activity and change of lipid pattern, activation of of lipolysis also leads to immunosuppressive effect. Hirudin the most potent natural inhibitor of thrombin, it is a direct thrombin inhibitor and does not require endogenous cofactors. Hirudin inhibits all actions of thrombin and so effectively inhibit coagulation and prevent heparin resistant arterial type thrombosis when given in large enough doses. Hirudin has no adverse effect when it is used into human, because it is pharmacologically inert. Hirudin is also a weak immunogen. Few researches evaluate the efficacy and drawbacks of Hirudin in HD patients. ;

Study Design

Related Conditions & MeSH terms

Haemodialysis

Clinical Trial Details

NCT number	NCT06112262
Study type	Interventional
Source	Assiut University
Contact	Basma Rabiey, Master
Phone	01128066349
Email	basmarabiey639@gmail.com
Status	Not yet recruiting
Phase	Early Phase 1
Start date	December 20, 2023
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01224314` - Potassium in Haemodialysis Fluids and Haemodynamics	N/A
Not yet recruiting	`NCT05525234` - A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus	Phase 4
Active, not recruiting	`NCT04139525` - Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane	N/A
Completed	`NCT02887742` - Epidemiologic Study and Impact Study of a Dialysis Solution Change on the Electrocardiographic Profile of Patient	N/A
Completed	`NCT01163981` - Ultrasound Guided Cannulation of Dialysis Fistulas	N/A
Recruiting	`NCT02902848` - Evaluation of the Validity of the Prothrombin Time Internation Normalised Ratio (PT/INR) Measured at the point-of Care on the Arterial Bloodline of Haemodialysis Extracorporeal Blood Flow	N/A
Completed	`NCT00718289` - Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes	Phase 4
Not yet recruiting	`NCT06225544` - Lumasiran in Hyperoxalaemic Patients on Haemodialysis	Phase 2
Completed	`NCT02707757` - Treatment Response in Dialysis Anaemia	Phase 4
Terminated	`NCT01382888` - Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis	Phase 2
Recruiting	`NCT00829153` - U Clip Study - Study to Compare U Clip Anastomosis With Conventional Continuous Prolene Anastomosis	Phase 1/Phase 2
Completed	`NCT00230906` - Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane	N/A
Not yet recruiting	`NCT05128188` - SASH: Sodium Accumulation Study In Haemodialysis
Completed	`NCT05729997` - Live Classical Music and the Response to the Disease and Its Evolution in Patients With Chronic Renal Failure	N/A
Active, not recruiting	`NCT02063776` - Haemodiafiltration vs Conventional Haemodialysis in Children	N/A
Completed	`NCT05280106` - Citrate Dialysate in Online Hemodialfiltration	N/A
Recruiting	`NCT04842591` - Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation
Recruiting	`NCT04260412` - The Effect of Combining Medium Cut Off Dialysis Membrane and Diet Modification on Reducing of Inflammation Response	N/A
Recruiting	`NCT04247867` - Combination of Medium Cut-off Dialyzer Membrane and Diet Modification to Alleviate Residual Uremic Syndrome of Dialysis Patients	N/A
Completed	`NCT00388661` - Melatonin and Quality of Life in Dialysis Patients	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison Between Haparin and Herodin in HD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms